60% of breast cancer patients carrying BRCA1 deleterious mutation were classified as triple-negative breast cancer, while only 10 to 20% were triple-negative breast cancer in unselected cancer patients (33, 34). This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.